CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $41.92, moving -1.2% from the previous trading session.

Researchers at the Experimental and Clinical Research Center (ECRC), a joint institution of the Max Delbrück Center and ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

CRISPR Therapeutics (CRSP) proposes to elect Briggs Morrison, M.D., to its Board of Directors at the Company’s annual general meeting to be ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

BofA analyst Alec Stranahan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $85 from $98 and keeps a Buy rating on the shares.

CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats. It is a component of bacterial immune systems that can cut DNA, and has been repurposed as a gene editing tool. CRISPR is ...

Check the time stamp on this data. Updated AI-Generated Signals for Crispr Therapeutics Ag (CRSP) available here: CRSP.

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

New Delhi, Jan. 02, 2025 (GLOBE NEWSWIRE) -- The global gene therapy market was valued at US$ 9.42 billion in 2024 and is projected to hit the market valuation of US$ 42.26 billion by 2033 at a CAGR ...